US 12,220,432 B2
Cardiac stem cells for cardiac repair
Sunjay Kaushal, Chicago, IL (US)
Assigned to University of Maryland, Baltimore, Baltimore, MD (US)
Filed by University of Maryland, Baltimore, Baltimore, MD (US)
Filed on Feb. 27, 2023, as Appl. No. 18/175,154.
Application 15/728,061 is a division of application No. 14/712,793, filed on May 14, 2015, abandoned.
Application 18/175,154 is a continuation of application No. 17/191,526, filed on Mar. 3, 2021, granted, now 11,633,431, issued on Apr. 25, 2023.
Application 17/191,526 is a continuation of application No. 15/728,061, filed on Oct. 9, 2017, granted, now 10,967,007, issued on Apr. 6, 2021.
Claims priority of provisional application 62/010,742, filed on Jun. 11, 2014.
Claims priority of provisional application 61/993,055, filed on May 14, 2014.
Prior Publication US 2023/0293597 A1, Sep. 21, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/34 (2015.01); A61K 38/18 (2006.01); A61K 38/19 (2006.01); A61P 9/10 (2006.01)
CPC A61K 35/34 (2013.01) [A61K 38/1833 (2013.01); A61K 38/1866 (2013.01); A61K 38/1891 (2013.01); A61K 38/19 (2013.01); A61K 38/195 (2013.01); A61P 9/10 (2018.01)] 9 Claims
 
1. A pharmaceutical composition comprising human, neonatal cardiac stem cells and a pharmaceutically acceptable carrier, wherein the human, neonatal cardiac stem cells:
(a) are positive for protein expression of ckit, SDF-1α, VEGF-A, PDGF-B, IL-6, FGF-2, and Nkx2.5,
(b) are negative for protein expression of ISL1; and
(c) are negative for protein expression of CD31, CD106, CD140b, or CD86.